

Study the effect of Lactoferrin Isolated and Purificated from Bovine milk and Colostrum on *E. coli* 0.157 isolated from diarrheic sheep

Abdulameer Jawad Zayier, Mungith Abdulmaged Alwan, and Asmaa Ibrahim Sail

Biotechnology Research Center, AL Nahrian University, Iraq

Correspondence Authors: Abdulameer Jawad Zayier, Biotechnology Research Center, AL Nahrian University, Iraq

Received date: 12 March 2023, Accepted date: 22 April 2023

Copyright: © 2023 authors., This open-access article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Human hemolytic uremic syndrome (HUS) and hemorrhagic colitis are both caused by *Escherichia coli* H7 serotype O157:H7 strains. A source of *E. coli* O157:H7 is cattle. We investigated whether bovine lactoferrin, a naturally occurring antimicrobial protein found in milk, could prevent the H7 *E. coli* O157 expansion. The results revealed that bovine lactoferrin, at respective dosages varying from 3 to 10 mg/ml, had a higher influence on *E. coli* O157:H7. LF of Bovine had no impact on the development of *this* strain, at respective dosages varying from 0.1 to 2 mg/ml.

Keywords: Lactoferrin, Bovine milk, Colostrum, *E. coli* 0.157

INTRODUCTION

Colostrum is a fluid produced and accumulated by the mammary glands within the first several days following calving and throughout the last trimester of pregnancy. It contains high-quality nutrition and physiologically active compounds to the calf. Colostrum is not only nourishing, stimulating, and protective, but it also possesses purgative properties. By causing meconium to evacuate through peristalsis, it stops the body from overdensifying and having excretion problems. Among the bioactive components with immune-stimulating properties present in Colostrum are lactoperoxidase, lactalbumin, lactoglobulin, fat that transports vital vitamins, antibodies, polyunsaturated fatty acids, lactoferrin, and lysozyme (Puppel et al., 2019).

Intriguingly, Lactoferrin has anti-oxidant, antiviral, anti-inflammatory, immunomodulatory, and anti-cancer characteristics in addition to its ability to promote the development of probiotic bacteria like *Bifidobacterium*. Various antifungal, antibacterial, and immunoregulating substances are also present (Christiansen and Kjelden, 2010). One of the most crucial proteins in mammalian milk is lactoferrin, an iron-binding protein. The most likely physiologically relevant action of lactoferrin is defense against gastroenteritis. Among the many pathogens present are the diarrhea-causing *Escherichia coli*, Rotavirus, *Giardia*, *Shigella*, and *Salmonella* (Ochoa & Cleary, 2009).

Less recent Sheep and goats, two small domestic ruminants, have emerged as significant reservoirs of *E. coli* O157:H7 human illness. Because of the increased consumption of sheep and goat foods, such as unpasteurized cheese, and the popularity of petting farms (La Ragione et al., 2009). *Escherichia coli* O157:H7 is a significant reservoir in ruminants, hence decreasing the amount of *E. coli* O157:H7 excreted by these animals may be crucial in lowering human infections (Yekta et al., 2011).

MATERIAL AND METHODS

A total of 10 sheep from diarrheal sheep were collected between January and December 2019 from veterinary offices and slaughterhouses in Baghdad City. Samples were taken on average eight to ten times per month from both genders, and each sample was placed in separate sterile cotton swabs with transport media (phosphate buffer saline) to prevent

contamination. Samples were then immedi transported to the lab in a cool box with ice packs. 45 ml of buffered peptone water (BPW) and one gram of enrichment were added, and the mixture was incubated for 24 hours at 37 c. An inoculum (100 ul) was applied to sorbitol MacConkey agar plates from the enrichments, which were subsequently cultured for a further 48 hours at 37°C, and 2.5 mg/l of tellurite and 0.05 mg/l of cefixime are added . Brain heart infusion broths (BHIB) containing 20%(vol/vol) glycerol were infused with suspected *E. coli* O157 colony cultures and stored at -80°C until DNA extraction was needed. The 16S rRNA gene unique to *E. coli* was amplified to validate the isolates based on growth, colony morphology, oxidase response, Gram stain, and TSI.

Samples of bovine colostrum interacting

samples obovine colostrum sampleslected from various locations across the Baghdad Governorate and promptly frozen before being kept at 18°C. Using centrifugation for 15-20 minutes at 4°C with an acceleration of 8,000 revolutions per minute, the frozen materials were defrosted.. After the casein from the skimmed colostrum was precipitated with 1 mol/L HCl at pH 4.2, the samples of skimmed bovine colostrum were frozen and kept at 18°C. and clostral whey was produced when microfiltration was used to remove the precipitated casein.. Then, cloistral whey was packaged in plastic containers and kept overnight at 4°C before usage. After being diluted ten times with distilled water, the cloistral whey was ultrafiltered (at 20 °C) in a bench-top setup using a 50 kD membrane as the cut-offostrum whey.




Figure 1. LF was isolated from the ultrafiltered colostrum whey using a CM-sepharose FF column (1.6 25 cm) and cation-exchange chromatography

Lactoferrin separations using ion exchange chromatography

CM Separose FF and DEAE Sepharose FF were used to absorb LF. The ultrafiltered whey underwent cation exchange chromatographic separation on a column made of CMsepharose FF measuring 1.6 25 cm, followed by anion exchange chromatographic separation using a DEAE-sepharose column with a diameter of 1.67 cm.. After the anion exchange columns had been cleansed with deionized water, stepwise sodium chloride solutions of increasing molarities were employed to elute them. The LF fractions were then dialyzed in sequence for an entseparates at the same speed. The cation was freeze-dried at 63°C and tested against pure water Figure 2.




Figure 2: Anion-exchange chromatography with a DEAE-sepharose FF column (1.6 75 cm) separates LF from ultrafiltrated colostrum whey.

MicrobiologyTo order to produce overnight cultures, a colony from a single well was inoculated into a 10-ml tube with Luria bro. The tube was incubated at 37°C for 24 hours while being shaken at 200 rpm. Each of the four strains of *E. coli* O157:H7 was tested for the antibacterial activity of LF. Centrifugation (11 337 g, 5 min) was used to pellet *E. coli* O157:H7 overnight cultures into 1 was subsequently reconstituted in 1 ml of LB medium. 100 CFU/ml of bacteria and then were cultured in LB broth with various amounts of bovine LF (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3 and 10 mg/ml) for 16 hours at 37°C.

RESULTS AND DISCUSSION

Results of Percentage of Isolation of *E.coli* O157

The results of bacterial isolation showed five bacterial isolates, from one hundred diarrheic fecal samples which were identified as *E.coli* and represent 5%, while 95 samples were gave negative results for bacterial culture from various urban and rural farm animals from different area in Baghdad governorate.

Genomic DNA extraction

The results demonstrate that the DNA of 5 isolaes was extracted favorably and appears as a compact band using a simple protocol genomic DNA Extraction kit (G-SPIN kit) **Figure 3.**




Figure 3: Show, result of whole extracted genomic DNA samples of 5 isolates on gel, using (1% agarose, TBE buffer (1X), 5 V/cm. for one hour, electrophoresis stained with red safe stain.

PCR results of *16srRNA* of *E.coli* 0157

The 5 suspected isolates of *E.coli* 0157 were confirmed by conventional PCR technique, amplification of bacterial genomic DNA was conducted by using two primers Under these optimal conditions, the expected fragment approximately 1250 bp of *16srRNA* gene were successfully amplified for as *E.coli* 0157 which were confirmed by the electrophoresis analysis The results showed that the investigated *E.coli* 0157 isolates had been correctly identified by genus When amplified PCR products, that created using the universal bacterial *16srRNA* primers, Figure 4.




Figure 4: PCR product the band size 1250 bp 16SrRNA. The product was electrophoresed on 1.5% agarose avoltsvolt/cm2. 1x TBE buffer for 1:30 hours. M: DNA ladder (100 -2000).: lane (1-30) represent (*E.coli* 0157humans in human) iUVlized under U.V light .

Analysis of The Nucleotide Sequence of Partial *16srRNA* Gene of *E.coli* 0157

Result analyses of Nucleotide Sequence of Partial *16srRNA* Gene of 78 isolates of *E.coli* 0157 that submitted in GenBank database showed 99% similarity or compatibility with the reference strains in GenBank, by using Blast and Bio edit Sequence alignment and can be found under the accession number at NCBI-GEN Bank as follow five accession numbers were obtained from *16SrRNA* and registration of 15 sequences of *16SrRNA* gene for human isolates include submission ID: CP044148.1 , C,3539.1 ; MK791711.1, C022050.2 : CP015832.1 belong to *E.coli* 0157 Figure(5).

Table 1: Analysis of The Nucleotide Sequence of Partial *16srRNA* Gene of *E.coli* 0157.

	Accession	Country	Host	Source	Compatibility
1.	ID: CP044148.1	USA	-----	Escherichia coli O157	99%
2.	ID: CP043539.1	United Arab Emirates	camel	Escherichia coli O157	99%
3.	ID: MK791711.1	Pakistan	chicken	Escherichia coli O157	99%
4.	ID: CP022050.2	USA: DC	Homo sapiens	Escherichia coli O157	99%
5.	ID: CP015832.1	United Kingdom	Homo sapiens	Escherichia coli O157	99%




Figure 5: Evolutionary relationships of taxa of E.coli O157

Results of cultural characteristics

E.coli. Produce distinct colonies on selective media emerged, whereas on chrome agar, the colonies were round blthe ue while Colony morphology of isolates of *E.coli* appear as smooth , small, pale and rounded colonies on sorbitol MacConkey agar (**Figure 6**)




Figure 6: Colony characteristics of *E.coli* O157 on selective media in (A) on chrome agar and (B) sorbitol MacConkey agar.

Lactoferrins' impact on the development of *E. coli* O157:H7

Both in vitro and in vivo investigations have demonstrated that lactoferrin inhibits the development of various harmful bacteria, including *E. coli* (Shashikumar and Puranik 2011). The development of *E. coli* O157:H7 bacteria was observed in various concentrations of bovine LF. Using (3 to 10 mg/ml, respectively), (figure 7) Growth of *Escherichia coli* O157:H7 was significantly inhibited between four and seven hours after incubation. Thus, *E. coli* O157:H7 was more effectively inhibited by bLF. Bovine LF, at doses ranging from 0.1 to 2 mg/ml, did not affect the growth of *E. coli* O157:H7. After removing the LF after 8 hours, bacteria were let to grow again in fresh medium.

The only levels of LF that stopped bacterial growth for an hour were 8 to 10 mg/ml. As a result, it is possible that bovine lactoferrins had bacteriostatic effects on *E. coli* O157:H7. From four to seven hours after incubation, lactoferrins significantly (at 3 to 10 mg/ml) inhibited growth. As a result, a considerable anti-microbial effect takes time to become apparent, as was also noted by Kawasaki et al. (2000). Also our study in computable with study by Rybarczyk *et al.*, (2017) They concluded that lactoferrin had an antibacterial effect against *E. coli* O157:H7 in both in vitro and in vivo experiments. This could be because of how slowly LF interacts with bacterial LPS, which is known to kill bacteria. Bacterial outer membranes frequently have phospholipids in the inner leaflet and lipopolysaccharide (LPS), a polyanionic glycolipid, in the outer leaflet.

Lactoferrin's ability to bind iron and decrease its availability in the growing environment is the reason for this., it displayed bacteriostatic effects at high doses (8 to 10/ml), which made its direct antibacterial action on *E. coli* O157:H7 greater our study matching with the study staed by(HASSAN *et al.*, 2022;Orsi, 2004). Who demonstrated that *Ecoli* O157 can be treated with high consternation of lactoferrin's In a different research, In broth from three to six hours after incubation, Atef Yekta et al. (2010) demonstrated that the growth of *E. coli* O157:H7 was considerably reduced when using 0.5 to 10 mg/ml and 0.1 to 10 mg/ml of human or bovine lactoferrin, respectively.

Additionally, Lactoferrin at concentrations of 10 and 20 mg/ml significantly decreased the viability of *E. coli* isolated after 72 hours in broth at all doses, according to (Taha *et al.* 2019).Also The bactericidal effects of LF binding to the surface of Gram-negative bacteria are initiated by the release of lipopolysaccharide (LPS) from the membrane (Ellison *et al.*, 1988; Orsi, 2004). The selective penetration of ions and disruption of the bacterial TTSS caused by the serine protease activity of LF are additional antibacterial actions attributed to it (Ochoa et al., 2003). On the other side, *E. coli* O157:H7 may have also devolved a bacterial defense mechanism that prevented lactoferrins from binding. This may help to explain why low doses of LF (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2 ml/ml) either had no impact or only temporarily inhibited development. According to Senkovich *et al.* (2007) and Kieckens *et al.*,2018 LF blockage may result from a contact with a bacterial surface protein or from porins being protected from LF interaction by LPS. (figure8).




Figure 7: concentrations of bovine LF. Using (3 to 10 mg/ml)




Figure 8: Concentrations of bovine LF. Using (0.1to 2 mg/ml)

CONCLUISON

In summary, this study contributes to the growing body of evidence supporting lactoferrin's potential as an effective antimicrobial agent against harmful bacteria like *E. coli* O157:H7. The results underscore the importance of dosage and duration in achieving significant inhibitory effects. Further research could delve into the specific interactions between lactoferrin and bacterial components, shedding light on the precise mechanisms underlying its antibacterial properties and potentially leading to the development of novel antimicrobial strategies.

REFERENCES

- Atef Yekta, M.; Verdonck, F.; Van Den Broeck, W.; Goddeeris, B.; Cox, E. and Vanrompy, D. (2010): Lactoferrin inhibits *E. coli* O157: H7 growth and attachment to intestinal epithelial cells *Veterinarni Medicin*, 55: 359-368
- Yekta MA, Cox E, Goddeeris BM, Vanrompay D(2011) Reduction of *Escherichia coli* O157:H7 excretion in sheep by oral lactoferrin administration. *Vet Microbiol.* 150(3-4):373-378.
- Jenny M, Pedersen N , Hidayat BJ, Schennach H, Fuchs D (2010): Bovine colostrum modulates immune activation cascades in human peripheral blood mononuclear cells *in vitro*. *New Microbiologica* 33, 129-135.
- Christiansen, S.; Guo, M.; Kjelden, D.(2010) Chemical composition and nutrient profile of low molecular weight fraction of bovine colostrum. *Int. Dairy J.*, 20, 630-636.
- Ochoa, T. J., & Cleary, T. G. (2009). Effect of lactoferrin on enteric pathogens. *Biochimie*, 91(1), 30-34. <https://doi.org/10.1016/j.biochi.2008.04.006>
- La Ragione, R. M., Best, A., Woodward, M. J., & Wales, A. D. (2009). *Escherichia coli* O157:H7 colonization in small domestic ruminants. *FEMS Microbiology Reviews*, 33(2), 394-410. <https://doi.org/10.1111/j.1574-6976.2008.00138.x>
- Schippa S, Lebba V, Barbaro M, Nardo GD, Totino V, Checchi MP, Longhi C, Maiella G, Cucchiara S and Conte MP (2010). A distinctive microbial signature' in celiac pediatric patients. *BMC Microbiology* 10: 175.

- Kieckens, E., Rybarczyk, J., Cox, E., & Vanrompay, D. (2018). Antibacterial and immunomodulatory activities of bovine lactoferrin against *Escherichia coli* O157:H7 infections in cattle. *BIOMETALS*, 31(3), 321–330. <https://doi.org/10.1007/s10534-018-0082>
- Kawasaki Y, Tazume S, Shimizu K, Matsuzawa H, Dosako S, Isoda H, Tsukiji M, Fujimura R, Muranaka Y, Isihida H (2000): Inhibitory effects of bovine lactoferrin on the adherence of enterotoxigenic *Escherichia coli* to host cells. *Bioscience Biotechnology and Biochemistry* 64, 348–354
- Orsi N (2004): The antimicrobial activity of lactoferrin: Current status and perspectives. *Biometals* 17, 189–196.
- Ellison RT, Giehl TJ, Laforce FM (1988): Damage of the outer membrane of enteric Gram negative bacteria by lactoferrin and transferrin. *Infection and Immunity* 56, 2774–2781.
- Ochoa TJ, Noguera-Obenza M, Ebel F, Guzman CA, Gomez HF, Cleary TG (2003): Lactoferrin impairs type III secretory system function in enteropathogenic *Escherichia coli*. *Infection and Immunity* 71, 5149–5155
- Naidu SS, Erdei J, Czirik E, Kalfas S, Gado I, Thoren A, Forsgren A, Naidu AS (1991): Specific binding of lactoferrin to *Escherichia coli* isolated from human intestinal infections. *Apmis* 99, 1142–1150
- Senkovich O, Cook WJ, Mirza S, Hollingshead SK, Protasevich II, Briles DE, Chattopadhyay D (2007): Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein A provides insight into microbial defense mechanism. *Journal of Molecular Biology* 370, 701–
- Shashikumar, C. and Puranik, D. (2011): Study on Use of Lactoferrin for the Biopreservation of Paneer. (2011). *Adv. Anim. Vet. Sci.* 6(11): 514-519
- Taha, N., El barbary, H., Ibrahim, E., Mohammed, H., & Wahba, N. (2019). Application of lactoferrin as a trial to control E. coli O1 and O26 in pasteurized milk. *Benha Veterinary Medical Journal*, 36(2), 360-366. doi: 10.21608/bvmj.2019.15172.1054
- Rybarczyk, Joanna, E. Kieckens, Daisy Vanrompay and Eric Cox.(2017) “In vitro and in vivo studies on the antimicrobial effect of lactoferrin against *Escherichia coli* O157:H7.” *Veterinary microbiology* 202 (2017): 23-28 .